We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Post-TAVR Pacemakers Linked to Higher Mortality Risk

By Daniel Beris
Posted on 22 Nov 2016
Permanent pacemaker (PPM) implantation soon after transcatheter aortic valve replacement (TAVR) often leads to worse outcomes, according to a new study.

Researchers at the Reading Health System (West Reading, PA, USA), Thomas Jefferson University (TJU; Philadelphia, PA, USA), and other institutions conducted a retrospective cohort study of 9,785 patients undergoing TAVR in the United States at 229 sites between November 2011 and September 2014. Of these, 651 needed a permanent pacemaker within 30 days of the TAVR procedure. The researchers then used the data to evaluate the incidence, predictors, and clinical outcomes of PPM implantation following TAVR.

The results showed that PPM needs varied among those receiving self-expanding valves (25.1%) versus balloon-expanding valves (4.3%). Positive predictors of PPM implantation were age, prior conduction defect, and use of self-expanding valve. PPM implantation was also associated with longer median hospital stay, intensive care unit (ICU) stay, increased mortality, and a composite of mortality or heart failure admission at one year, but not with heart failure admission alone. The study was published in the November 2106 issue of JACC: Cardiovascular Interventions.

“While pacemakers can and do help save lives, what our study shows is that when they are placed within a month post-TAVR, they may be associated with worsened outcomes as compared to those who did not need pacemakers,” said lead author Opeyemi Fadahunsi, MBBS, MPH, of Reading Health System. “While TAVR is a great advance in medical care, cardiologists need to better understand both how to prevent patients from developing heart rhythm problems, and why patients who need pacemakers in the setting of recent TAVR have worsened outcomes.”

The percutaneous treatment of severe aortic valve disease using a TAVR prosthetic aortic valve replacement, without the need for open-heart surgery or cardiopulmonary bypass, is faster and less invasive than current open-heart procedures. TAVR has so far been proven effective in high-risk and inoperable patients, and could soon become the standard of care, even in moderate and low surgical risk patients.

Related Links:
Reading Health System
Thomas Jefferson University

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Needlefree Closed System Transfer Device
ChemoClave

Latest Surgical Techniques News

Living Knee Replacement to Revolutionize Osteoarthritis Treatment

Soft, Flexible, Battery-Free Implant Continuously Monitors Bladder Function

AR Headset-Enhanced Abdominal Surgery Empower Surgeons to Perform More Efficient Procedures